We use essential cookies (authentication, your saved goals/stack) by default. With your permission we’ll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Tir7.8
Tirzepatide Research
Mostly mechanism / observational
90 peer-reviewed studies
What the evidence says
Mostly mechanism / observational
Most Tirzepatide studies are mechanism or observational rather than RCTs that measure a clinical effect — keep findings provisional.
Most evidence is from high-quality meta-analyses and randomised trials published 2021–2026 with a typical study size of 1,995 participants.
Based on 90 studies · 33 meta-analyses · 45 RCTs · 452,378 total participants
Confidence
High confidence
By outcome
Weight managementMean weight reductions up to ~21% over 72 weeks in obesity trials — the largest of any approved weight-loss drug to date, superior to semaglutide head-to-head · Months (dose-escalated over ~20 weeks)
Mostly mechanism / observational61 studies
Glycemic & metabolic controlLowers HbA1c by roughly 1.9-2.6 percentage points in phase-3 diabetes trials; superior to basal insulin and semaglutide 1 mg head-to-head · Weeks to months · Combined large weight loss and strong glycemic control improve overall metabolic status · Months
Mostly mechanism / observational40 studies
Safety profile
Mostly mechanism / observational15 studies
Heart & blood pressure
Mostly mechanism / observational14 studies
Sleep apnea & respiratory
Mostly mechanism / observational4 studies
Active research area
90 studies in the last 5 years · Latest meta-analysis: 2026
20212026
1Meta-Analysisn=199,877 · very large study2026
Further prospective trials are needed to clarify causal mechanisms and inform clinical decision-making.
Liang CS et al. · International journal of molecular sciences (2026)
Odds ratios (ORs) with 95% credible intervals (CrIs) were calculated, and surface under the cumulative ranking curves (SUCRA) were used to estimate relative safety rankings.
Only high-dose tirzepatide (10-15 mg/week) was associated with a significantly increased risk of AKI compared to controls (absolute risk difference: 0.28%; number needed to harm: 357).
Funding World Health Organization (WHO) REGISTRATION: Protocol (2022) DOI: 10.1002/14651858.CD015092 Updated Protocol (2025): PROSPERO CRD420250654193.
Franco JV, Guo Y, Varela LB, Aqra Z, Alhalahla M, Medina Rodriguez M, Salvador Oscco EL, Patiño Araujo B, Banda S, Escobar Liquitay CM, Bracchiglione J, Meza N, Madrid E. · The Cochrane database of systematic reviews (2025)
Tirzepatide may result in an increase in non-serious adverse events (RR 1.33, 95% CI 1.03 to 1.71; 5 studies, 4582 participants; low-certainty evidence).
The evidence is very uncertain about the effect on serious adverse events (RR 0.99, 95% CI 0.88 to 1.12; 8 studies, 6359 participants; very low-certainty evidence).
Tirzepatide may result in little to no difference in adverse events leading to withdrawal (RR 2.06, 95% CI 1.21 to 3.52; 8 studies, 6359 participants; low-certainty evidence).
Due to the limited number of trials for tirzepatide and lanifibranor, further large-scale studies are warranted to confirm their role in MASLD/MASH management.
Zhao S et al. · Internal and emergency medicine (2026)
The analysis included 2497 individuals (1112 [45%] male, mean age 55.6 years [SD 11.6], mean BMI 35.3 kg/m2 [SD 6.3], and 1385 [55%] with diabetes).
Tirzepatide (mean difference [MD] - 34.90% [95% CI: - 53.31 to - 16.49]) and resmetirom (MD - 31.45% [95% CI: - 35.93 to - 26.97]) significantly reduced hepatic steatosis as assessed by magnetic resonance imaging-proton density fat fraction (MRI-PDFF).
Tirzepatide significantly reduced serum aminotransferase levels (ALT: MD - 30.90%, p < 0.00001; AST: MD - 20.71%, p < 0.00001).
The use of GLP-1 RAs is significantly associated with an increased risk of hair loss.
Cheng PL et al. · Diabetes research and clinical practice (2026)
The pooled analysis revealed a significantly higher risk of hair loss in GLP-1 RA users than in placebo users (risk ratio [RR]: 3.252; 95% confidence interval [CI]: 1.437 to 7.358).
The significant results persisted even when the analysis was restricted to RCTs focusing on patients with overweight or obesity (RR: 3.587; 95% CI: 2.100 to 6.124).
Furthermore, a single-arm analysis revealed that the event rate of hair loss following GLP-1 RA therapy was 3.9%.
Among people with type 2 diabetes and atherosclerotic cardiovascular disease, tirzepatide was associated with a reduced risk of major kidney events compared with dulaglutide, primarily driven by a reduction in new-onset macroalbuminuria in people with low-to-moderate-risk chronic kidney disease, and slowed decline in kidney function in people with high-risk chronic kidney disease.
Zoungas S et al. · The lancet. Diabetes & endocrinology (2026)
Clinical trial examining Tirzepatide efficacy
Published in The lancet. Diabetes & endocrinology (2026)
These findings suggest tirzepatide enhances perceived physical capacity and quality of life, although the extremely high between-study heterogeneity limits the interpretability of pooled estimates and warrants cautious interpretation.
Schmidt PHS, de Souza VSN, Machado LG, Rodrigues JVA, da Cruz JVR, de Souza LSN, Dos Santos BE, Hohl A, Ronsoni MF, van de Sande-Lee S. · Diabetes, obesity & metabolism (2026)
Random-effects models were used to calculate pooled mean differences (MD) with 95% confidence intervals (CI).
Tirzepatide significantly improved physical function compared with placebo, both in SF-36 physical function (MD 2.26 points; 95% CI, 1.76-2.76; I 2 = 99.8%; p < 0.001) and IWQOL-Lite-CT physical function (MD 10.10 points; 95% CI, 8.61-11.60; I 2 = 99.8%; p < 0.001).
Conclusions Tirzepatide 10 and 15 mg once weekly significantly improve patient-reported physical function in adults with overweight or obesity.